



Özkayı n et al <sup>[17]</sup>	2015	Turkey	RCT	H	33	83.94	10/23	A1: 4	31.33	52.33 ±	NA	5.55	68.63	1	0/33
				A		± 4.92		A2: 16	± 10.65	10.457		± 1.92	± 10.21		
Jolly et al <sup>[18]</sup>	2019	India	RCT	PF	21	79.57	9/12	A1: 4	32.33	28.19 ±	NA	6.02	77.57	3	1/20
				N		± 4.83		A2: 7	± 10.97	12.044		± 2.85	± 7.724		
Jolly et al <sup>[18]</sup>	2019	India	RCT	B	50	78.7 ±	NA	NA	12	60.4 ±	187 ±	NA	70.3 ±	26	NA
				H		8.3				9.9	38.1		18.7		
Jolly et al <sup>[18]</sup>	2019	India	RCT	PF	50	81.2 ±	NA	NA	12	48.4 ±	46 ±	NA	86.7 ±	38	NA
				N		7.8				6.4	13.5		13.1		

---

PFN: Proximal femoral nail; RCT: Randomized controlled trial.

**Supplementary Table 2 Complications described in studies**

Author	Year	Country	Study design	Group	No. of patients	Beds	Urinary tract infection	Superficial infection	Deep infection	Respiratory infection	Implant-related complication	Venous thromboembolism	Mortality (overall)	Weight-bearing time
Kim <i>et al</i> <sup>[14]</sup>	2005	Korea	RCT	HA	29	NA	NA	1	0	3	1	1	16	7.8 ± 1.6 (d)
				PFN	29	NA	NA	1	0	4	4	0	5	8.8 ± 2.9 (d)
Desteli <i>et al</i> <sup>[15]</sup>	2015	Turkey	RCT	BHA	44	NA	NA	4	NA	NA	0	NA	2	NA
				PFNA	42	NA	NA	4	NA	NA	0	NA	4	NA
				NA										
Özkaşın <i>et al</i> <sup>[17]</sup>	2015	Turkey	RCT	HA	33	NA	NA	1	0	NA	0	NA	NA	NA
				PFN	21	NA	NA	0	1	NA	0	NA	NA	NA

Jolly	20	India	BH	50	4	4	8	4	4	10	2	12	3.2 ±
<i>et</i>	19		A										4.7(
<i>al</i> <sup>[18]</sup>			RC										wk)
			T	PF	50	16	8	4	0	4	6	6	10.1
				N									±
													3.5(
													wk)

---

PFN: Proximal femoral nail; RCT: Randomized controlled trial.